Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma | Zendy

William D. Tap | Zendy; Víctor M. Villalobos | Zendy; Gregory M. Coté | Zendy; Howard A. Burris | Zendy; Filip Janků | Zendy; Olivier Mir | Zendy; M. Beeram | Zendy; Andrew J. Wagner | Zendy; Liewen Jiang | Zendy; Bin Wu | Zendy; Sung Choe | Zendy; Katharine Yen | Zendy; Camelia Gliser | Zendy; Bin Fan | Zendy; Sam Agresta | Zendy; Shuchi S. Pandya | Zendy; Jonathan C. Trent | Zendy

Open Access

Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma

Author(s) -

William D. Tap,

Víctor M. Villalobos,

Gregory M. Coté,

Howard A. Burris,

Filip Janků,

Olivier Mir,

M. Beeram,

Andrew J. Wagner,

Liewen Jiang,

Bin Wu,

Sung Choe,

Katharine Yen,

Camelia Gliser,

Bin Fan,

Sam Agresta,

Shuchi S. Pandya,

Jonathan C. Trent

Publication year - 2020

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.19.02492

Subject(s) - medicine , chondrosarcoma , adverse effect , idh1 , oncology , isocitrate dehydrogenase , surgery , mutant , enzyme , biochemistry , chemistry , gene

Surgery is the primary therapy for localized chondrosarcoma; for locally advanced and/or metastatic disease, no known effective systemic therapy exists. Mutations in the isocitrate dehydrogenase 1/2 (IDH1/2) enzymes occur in up to 65% of chondrosarcomas, resulting in accumulation of the oncometabolite D-2-hydroxyglutarate (2-HG). Ivosidenib (AG-120) is a selective inhibitor of mutant IDH1 approved in the United States for specific cases of acute myeloid leukemia. We report outcomes of patients with advanced chondrosarcoma in an ongoing study exploring ivosidenib treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research